AI
TRML

Acuitas Investments’s Tourmaline Bio TRML Stock Holding History

Acuitas Investments’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,455
Closed -$547K – 126
2023
Q3 		$547K Sell
19,455
-29,659
-60% -$868K 0.32% 79
2023
Q2 		$1.49M Buy
+49,114
New +$1.25M 0.87% 48

Other funds holding TRML

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Acuitas Investments's TRML Position: Q4 2023 in Review

Acuitas Investments sold out of Tourmaline Bio (TRML) in Q4 2023, closing a stake of 19,455 shares — an estimated $547K sold.

Acuitas Investments first reported a position in TRML in Q2 2023 and held it in 2 quarters. The position peaked at $1.49M in Q2 2023. 54 funds tracked by Wall St. Rank hold TRML as of Q4 2023.

  • Acuitas Investments reported no remaining Tourmaline Bio position as of Q4 2023 after selling out during the quarter.
  • Acuitas Investments sold 19,455 Tourmaline Bio shares in Q4 2023, an estimated $547K.
  • Acuitas Investments first reported a position in Tourmaline Bio in Q2 2023 and held it in 2 quarters.
  • Acuitas Investments's Tourmaline Bio position peaked at $1.49M in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2023.

Based on Acuitas Investments's 13F filing for Q4 2023, filed 2 Feb 2024.